FDA Approves Lantheus' Tauklarify PET Imaging Agent for Alzheimer's Assessment
核心洞察
The U.S. FDA approved Lantheus Holdings (搜索)' Tauklarify (搜索), a radioactive tau-targeting agent used with PET scans to help assess adults with cognitive impairment for Alzheimer's disease (搜索).
Approval was supported by two studies in which independent readers classified Tauklarify (搜索) PET scans from more than 500 participants as positive or negative for tau pathology.
Tauklarify (搜索) enters a market dominated by Eli Lilly's Tauvid (approved 2020), with analysts forecasting annual Tauklarify sales of less than $50 million by 2030.
The U.S. Food and Drug Administration has approved a radioactive agent from Lantheus Holdings (搜索) for use in brain scans to help assess patients for Alzheimer's disease (搜索), the company said on Friday. The agent, branded as Tauklarify (搜索), is injected before a positron emission tomography (PET) scan and makes abnormal deposits of tau proteins linked to Alzheimer's visible in images of the brain in adults with cognitive impairment who are being assessed for the disease.
A positive scan does not necessarily confirm tau pathology, while a negative scan does not rule it out, the company said.
Clinical Evidence Supporting Approval
The approval was supported by two studies in which independent readers assessed Tauklarify (搜索) PET scans from more than 500 participants and classified them as positive or negative for tau pathology.
Disease Burden and Pathophysiology
More than 7 million people in the United States have Alzheimer's, and the number of people aged 65 or older with the disease could exceed 13 million by 2050, Lantheus said.
Alzheimer's is a progressive brain disease and the most common cause of dementia, gradually damaging memory, thinking and the ability to perform everyday tasks. It is associated with abnormal deposits of beta-amyloid (搜索) and tau proteins in the brain. Amyloid can begin accumulating years before symptoms appear, while the amount and spread of tau are more closely linked to worsening memory and thinking problems.
Competitive Landscape
Tauklarify (搜索) will compete with Eli Lilly's Tauvid, which was approved in 2020 for use with PET scans to estimate the amount and distribution of tau deposits in adults being assessed for Alzheimer's disease (搜索). The tau-imaging market is dominated by Tauvid and is probably worth less than $100 million annually, B. Riley Securities analyst Yuan Zhi told Reuters. Zhi forecasts annual Tauklarify sales of less than $50 million by 2030.
Unlike beta-amyloid (搜索) imaging agents such as Lantheus' Neuraceq, the clinical use of tau imaging remains limited because there is no approved Alzheimer's treatment targeting tau, Zhi said.
Portfolio Expansion and Corporate Context
The approval expands Lantheus' Alzheimer's imaging portfolio by adding a tau-targeting agent alongside Neuraceq, its approved amyloid imaging agent. Earlier this month, privately-held radiopharmaceutical company Curium (搜索) agreed to buy Lantheus in a deal valued at up to $8 billion to expand its diagnostic and therapeutic radiopharmaceutical business. The transaction is expected to close in the first half of 2027.